기사

[CEO SIM SU JA]

Prodizen Co., Ltd. has been awarded the Grand Prize in the Medical category at the 2026 Korea Industry Awards.

The company was recognized for going beyond the first commercialization of PRP (Platelet-Rich Plasma) in Korea, achieving registration of new medical technologies and expanding exports to 30 countries, thereby strengthening the global presence of K-Bio.

Founded in 1998, Prodizen’s subsidiary Medisarang successfully commercialized Korea’s first PRP product in 2008 and registered it with the Ministry of Food and Drug Safety. PRP is a medical technology in which a patient’s blood is collected, centrifuged, and the platelet-derived growth factors are re-injected into the target area. All manufacturing processes are handled in-house by Medisarang.

In 2019, through joint R&D with major hospitals—including Samsung Medical Center, Catholic Medical Center, and Chosun University Hospital—the company became the first in Korea to achieve new medical technology designation in orthopedics. Since then, its applications have expanded to ophthalmology and obstetrics & gynecology, driving the broader adoption of PRP.

Prodizen has also demonstrated strong capability in translating technology into market success. It has obtained U.S. FDA Class II clearance and European CE certification, and was the first Korean company to complete product registration in both the United States and China. The company currently exports to more than 30 countries and was awarded the "$1 Million Export Tower" in 2023.

Through a distribution agreement with Canadian medical company Clarion Medical, Prodizen aims to achieve over USD 3 million (approximately KRW 4.4 billion) in exports by 2027.

CEO Sim Suja stated, “We will continue to contribute to healthier lives through the steady development of cell therapy technologies.”

Sohee Ahn, Reporter (ash0303@donga.com)